deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT03041012

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART (eCLEAR)

Early Administration of Latency Reversing Therapy and Broadly Neutralizing Antibodies to Limit the Establishment of the HIV-1 Reservoir During Initiation of Antiretroviral Treatment - a Randomized Controlled Trial

Sponsor: Aalborg University Hospital

Conditions Hiv
Updated 17 times since 2017 Last updated: Apr 15, 2025 Started: Jan 20, 2017 Primary completion: Aug 20, 2021 Completion: Dec 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03041012, this PHASE2 trial focuses on Hiv and remains completed. Sponsored by Aalborg University Hospital, it has been updated 17 times since 2017, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Study Description(click to expand)

The study will be conducted among ART naïve HIV-1-infected patients. Subjects will continue ART while receiving LRA romidepsin and/or bNAb 3BNC117.

The study will be conducted among ART naïve HIV-1-infected patients.

Subjects will continue ART while receiving LRA romidepsin and/or bNAb 3BNC117.

Status Flow

~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~May 2019 · 4 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Nov 2019 · 5 months · monthly snapshot~Nov 2019 – ~Oct 2020 · 11 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Oct 2021 · 5 months · monthly snapshot~Oct 2021 – ~May 2023 · 19 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot

Change History

17 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Present [monthly]

    Completed PHASE2

  3. May 2025 — Sep 2025 [monthly]

    Completed PHASE2

    Status: UnknownCompleted

  4. Sep 2024 — May 2025 [monthly]

    Unknown PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown StatusUnknown

Show 12 earlier versions
  1. May 2023 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Active Not RecruitingUnknown Status

  2. Oct 2021 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  3. May 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  6. Nov 2019 — Oct 2020 [monthly]

    Recruiting PHASE2

  7. Jun 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  8. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  9. Jan 2019 — May 2019 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  11. May 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  12. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aalborg University Hospital
  • Aarhus University Hospital
  • Hammersmith Hospitals NHS Trust
  • Herning Hospital
  • Hvidovre University Hospital
  • Odense University Hospital
  • Rigshospitalet, Denmark
  • St Mary's Hospital, London
Data source: University of Aarhus

For direct contact, visit the study record on ClinicalTrials.gov .